Recent Updates
Recently added Catalysts

REC-7735

Phase 1

Solid Tumors | Small molecule | Other |Recursion Pharmaceuticals, Inc.|Last Updated: Sep 14, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment90

FDA Designations

No designations recorded

Clinical trial landscape

REC-7735 · 1 trial · 1 indication

Phase 1 1
NCT07819136REC-7735 in Participants With Solid TumorsSolid Tumors
NOT YET_RECRUITING90 Analytics
PHASE1NOT YET_RECRUITING
REC-7735 in Participants With Solid Tumors
Solid Tumors
NCT0781913690
Unlock trial analytics

Study Endpoints

Primary Endpoints

Phase 1A: Number of Participants With Dose-limiting Toxicities (DLTs)
28 days
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Up to 2 years
Phase 1B: Objective Response Rate (ORR) According to Standard Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Up to 2 years

Secondary Endpoints

Maximum (Peak) Drug Concentration (Cmax) of REC-7735
Up to 2 years
Time to Reach Cmax following drug administration (Tmax) of REC-7735
Up to 2 years
Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of REC-7735
Up to 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 1A Dose Finding: REC-7735EXPERIMENTALParticipants will receive REC-7735 twice daily (BID).
Phase 1B Dose Expansion/Optimization: REC-7735EXPERIMENTALParticipants will receive REC-7735 BID.

Interventions

NameTypeDescription
REC-7735DRUGOral
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Key Inclusion Criteria: * Participants have histologically-confirmed unresectable, locally advanced, or metastatic solid tumors which exhibit the PIK3CA H1047R mutation in tumor tissue and/or blood (circulating tumor deoxyribonucleic acid \[ctDNA\]). * For Phase 1A and planned monotherapy cohorts i...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Solid Tumors")

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2Pembrolizumab, Gardasil 9
Incyte CorporationINCY1PHASE2Retifanlimab
Iovance Biotherapeutics IncIOVA2PHASE2Aldesleukin
Novartis AG Sponsored ADRNVS1PHASE1KFA115
AstraZeneca PLCAZN1 - Trastuzumab deruxtecan
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWSep 15, 2026NCT07819136NEW_TRIAL: changed
LOWSep 15, 2026NCT07819136NEW_TRIAL: changed
LOWSep 15, 2026NCT07819136NEW_TRIAL: changed